The S&P 500 Index ($SPX ) (SPY ) closed down by -1.09% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.50%. December E-mini S&P futures (ESZ26 ) fell -1.14%, and December E-mini...
(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL), a clinical oncology company, on Sunday announced interim overall survival (OS) data from the Phase 2 DENALI Part 1b trial for azenosertib as a biomarker-driven treatment for ovarian cancer.
(RTTNews) - Cleveland-Cliffs (CLF) reported third quarter GAAP net income of $165 million, or $0.26 per diluted share, compared to a loss of $234 million or $0.51 per share, prior year. Adjusted EBITDA was $612 million, compared to $143 million, last year. The company recorded an
(RTTNews) - German stocks tumbled on Monday as growing unrest in France, political tensions in Eastern Europe, persisting worries about Middle East conflict and concerns about elevated oil prices rendered the mood bearish.
The S&P 500 Index ($SPX ) (SPY ) closed down by -1.09% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.50%. December E-mini S&P futures (ESZ26 ) fell -1.14%, and December E-mini...
(RTTNews) - Indian shares fell sharply on Monday due to concerns over persistent foreign investor outflows and elevated crude oil prices in international markets.
(RTTNews) - OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi sponsored by FoRT and evaluating Tedopi (OSE2101), in combination with either chemotherapy or anti-P
(RTTNews) - Disc Medicine, Inc. (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial evaluating Bitopertin in patients with erythropoietic protoporphyria (EPP), a rare inherited blood disorder. The company will discuss the findings during a corporate
(RTTNews) - One in two pediatric ulcerative colitis patients who responded to initial treatment with Omvoh remained in clinical remission after one year in a Phase 3 study, as Eli Lilly and Company (LLY) reported positive results from the SHINE-2 trial evaluating the therapy in c